Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Conditions

• Primary Myelofibrosis
• Post-Polycythemia Vera Myelofibrosis
• Post-Essential Thrombocythemia Myelofibrosis
• Polycythemia Vera
• Essential Thrombocythemia

Interventions

• DRUG: Momelotinib

Sponsor

Sierra Oncology LLC - a GSK company